Is advanced renal cell carcinoma becoming a chronic disease?
Larkin
James
J
Renal Cancer Unit, Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, UK. james.larkin@rmh.nhs.uk
Gore
Martin
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D006801:Humans; D007191:Indazoles; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D007680:Kidney Neoplasms / Q000473:pathology*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015398:Signal Transduction; D013449:Sulfonamides / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D000970:Antineoplastic Agents; D007191:Indazoles; D047908:Intracellular Signaling Peptides and Proteins; D011743:Pyrimidines; D013449:Sulfonamides; D042461:Vascular Endothelial Growth Factor A; C516667:pazopanib; C546842:MTOR protein, human; D020794:Receptor Protein-Tyrosine Kinases; D017346:Protein Serine-Threonine Kinases; D058570:TOR Serine-Threonine Kinases